News-Medical.Net on MSN
Newly discovered survival pathway explains stubborn EGFR-driven lung cancers
Scientists from A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB) have identified why certain lung cancer cells ...
Clinicopathologic features and treatment outcomes of patients (pts) with HER2-positive (pos) adenocarcinomas (ACA) of the esophagus (E) and gastroesophageal junction (GEJ). This is an ASCO Meeting ...
Edward Arrowsmith, MD, MPH, medical director for clinical pathways for OneOncology, discussed treatment challenges in EGFR Exon 20 insertion+ non-small cell lung cancer (NSCLC) and best practices in ...
Clinical relevance of insulin regulatory pathways in non-small cell lung cancer (NSCLC) progression.
Impact of EGFR and KRAS mutations on survival in 1,000 patients with resected lung adenocarcinoma. Background: Insulin and insulin-like growth factors are key regulators of normal metabolism and ...
Significant association seen for eGFR percentiles below the 25th percentile with risk for kidney failure with replacement ...
Suresh Ramalingam, MD, FACP, FASCO, a professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine, is the executive director of the Winship Cancer Institute ...
Schematic diagram of the IL-6/JAK/STAT3 signaling pathway activation in mouse liver macrophages. IRs, inhibitory receptors (IRs); ICIs, immune checkpoint inhibitors; IL-6, interleukin-6; ALT, alanine ...
EGFR-positive lung cancer is a subtype of non-small cell lung cancer (NSCLC) caused by an epidermal growth factor receptor (EGFR) gene mutation that drives cancer growth. Common EGFR mutations (exon ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results